PrimeC Performs Well in High-Risk ALS, Patient Death Reported in DAYLIGHT Trial, Donanemab AdComm Hearing Date Announced
WATCH TIME: 4 minutes Welcome to this special edition of Neurology News Network. I’m Marco Meglio. Newly announced analyses from the phase 2b PARADIGM trial showed that treatment with PrimeC (NeuroSense), an investigational agent, resulted in statistically …